O	0	5	Local
O	6	16	anesthetic
O	17	25	delivery
O	26	29	via
B-intervention	30	38	surgical
I-intervention	39	44	drain
O	45	53	provides
O	54	62	improved
B-condition	63	67	pain
O	68	75	control
O	76	82	versus
B-control	83	89	direct
I-control	90	94	skin
I-control	95	107	infiltration
O	108	117	following
O	118	126	axillary
O	127	131	node
O	132	142	dissection
O	143	146	for
O	147	153	breast
O	154	160	cancer
O	160	161	.

O	162	170	Axillary
O	171	175	node
O	176	186	dissection
O	187	190	has
O	191	192	a
O	193	200	central
O	201	205	role
O	206	208	in
O	209	212	the
O	213	221	surgical
O	222	232	management
O	233	235	of
O	236	242	breast
O	243	249	cancer
O	249	250	;
O	251	258	however
O	258	259	,
O	260	262	it
O	263	265	is
O	266	276	associated
O	277	281	with
O	282	283	a
O	284	295	significant
O	296	300	risk
O	301	303	of
O	304	315	lymphoedema
O	316	319	and
O	320	327	chronic
O	328	332	pain
O	332	333	.

O	334	338	Peri
O	338	339	-
O	339	348	operative
O	349	363	administration
O	364	366	of
O	367	372	local
O	373	383	anesthesia
O	384	391	reduces
O	392	397	acute
O	398	401	and
O	402	412	persistent
O	413	417	post
O	417	418	-
O	418	426	surgical
O	427	431	pain
O	431	432	,
O	433	436	but
O	437	442	there
O	443	445	is
O	446	455	currently
O	456	458	no
O	459	468	consensus
O	469	471	on
O	472	475	the
O	476	483	optimal
O	484	490	method
O	491	493	of
O	494	499	local
O	500	510	anesthetic
O	511	519	delivery
O	519	520	.

B-eligibility	521	529	Patients
I-eligibility	530	540	undergoing
I-eligibility	541	549	axillary
I-eligibility	550	560	dissection
I-eligibility	561	564	for
I-eligibility	565	571	breast
I-eligibility	572	578	cancer
O	579	583	were
O	584	592	randomly
O	593	601	assigned
O	602	604	to
O	605	612	receive
O	613	614	a
O	615	618	one
O	618	619	-
O	619	622	off
O	623	627	dose
O	628	630	of
O	631	646	levobupivacaine
O	647	648	0
O	648	649	.
O	649	650	5
O	650	651	%
O	652	653	(
O	653	655	up
O	656	658	to
O	659	660	2
O	661	663	mg
O	663	664	/
O	664	666	kg
O	666	667	)
O	668	677	following
O	678	685	surgery
O	685	686	,
O	687	693	either
O	694	697	via
O	698	701	the
O	702	710	surgical
O	711	716	drain
O	717	719	or
O	720	722	by
O	723	729	direct
O	730	734	skin
O	735	747	infiltration
O	747	748	.

O	749	753	Post
O	753	754	-
O	754	763	operative
O	764	768	pain
O	769	776	control
O	777	779	at
O	780	784	rest
O	785	788	and
O	789	791	on
O	792	800	shoulder
O	801	810	abduction
O	811	814	was
O	815	823	assessed
O	824	829	using
O	830	831	a
O	832	841	numerical
O	842	848	rating
O	849	854	scale
O	854	855	.

O	856	861	Total
O	862	871	analgesia
O	872	883	consumption
O	884	886	48
O	887	888	h
O	889	894	after
O	895	902	surgery
O	903	906	was
O	907	911	also
O	912	920	recorded
O	920	921	.

B-outcome	922	926	Pain
I-outcome	927	933	scores
O	934	938	were
O	939	952	significantly
O	953	958	lower
O	959	963	when
O	964	969	local
O	970	980	anesthesia
O	981	984	was
O	985	997	administered
O	998	1001	via
O	1002	1010	surgical
O	1011	1016	drain
O	1017	1019	at
O	1020	1024	both
O	1025	1026	3
O	1027	1030	and
O	1031	1033	12
O	1034	1035	h
O	1036	1041	after
O	1042	1049	surgery
O	1049	1050	;
O	1051	1055	this
O	1056	1061	trend
O	1062	1070	extended
O	1071	1073	to
O	1074	1076	24
O	1077	1078	h
O	1079	1083	post
O	1083	1084	-
O	1084	1095	operatively
O	1095	1096	.

O	1097	1104	However
O	1104	1105	,
B-outcome	1106	1110	pain
I-outcome	1111	1117	scores
I-outcome	1118	1120	on
I-outcome	1121	1129	shoulder
I-outcome	1130	1139	abduction
O	1140	1143	did
O	1144	1147	not
O	1148	1154	differ
O	1155	1157	at
O	1158	1161	the
O	1162	1164	12
O	1165	1167	or
O	1168	1170	24
O	1171	1172	h
O	1173	1177	time
O	1178	1184	points
O	1184	1185	.

O	1186	1188	No
O	1189	1200	differences
O	1201	1205	were
O	1206	1211	found
O	1212	1214	in
O	1215	1218	the
B-outcome	1219	1224	total
I-outcome	1225	1234	analgesia
I-outcome	1235	1246	consumption
I-outcome	1247	1249	or
I-outcome	1250	1256	length
I-outcome	1257	1259	of
I-outcome	1260	1268	hospital
I-outcome	1269	1273	stay
O	1274	1281	between
O	1282	1291	treatment
O	1292	1298	groups
O	1298	1299	.

O	1300	1304	This
O	1305	1310	study
O	1311	1323	demonstrates
O	1324	1328	that
O	1329	1334	local
O	1335	1345	anesthetic
O	1346	1354	delivery
O	1355	1358	via
O	1359	1360	a
O	1361	1369	surgical
O	1370	1375	drain
O	1376	1384	provides
O	1385	1393	improved
O	1394	1398	pain
O	1399	1406	control
O	1407	1415	compared
O	1416	1418	to
O	1419	1425	direct
O	1426	1430	skin
O	1431	1443	infiltration
O	1444	1453	following
O	1454	1462	axillary
O	1463	1467	node
O	1468	1478	dissection
O	1478	1479	.

O	1480	1484	This
O	1485	1487	is
O	1488	1494	likely
O	1495	1497	to
O	1498	1500	be
O	1501	1510	important
O	1511	1514	for
O	1515	1518	the
O	1519	1529	management
O	1530	1532	of
O	1533	1538	acute
O	1539	1543	pain
O	1544	1546	in
O	1547	1550	the
O	1551	1560	immediate
O	1561	1565	post
O	1565	1566	-
O	1566	1575	operative
O	1576	1582	period
O	1582	1583	;
O	1584	1591	however
O	1591	1592	,
O	1593	1600	further
O	1601	1608	studies
O	1609	1612	may
O	1613	1615	be
O	1616	1624	required
O	1625	1627	to
O	1628	1636	validate
O	1637	1641	this
O	1642	1644	in
O	1645	1653	specific
O	1654	1661	patient
O	1662	1671	subgroups
O	1671	1672	,
O	1673	1674	e
O	1674	1675	.
O	1675	1676	g
O	1676	1677	.
O	1677	1678	,
O	1679	1685	breast
O	1685	1686	-
O	1686	1696	conserving
O	1697	1704	surgery
O	1705	1711	versus
O	1712	1722	mastectomy
O	1722	1723	.
